| II-17 Peter Bloomingdale An Artificial Intelligence Framework for Optimal Drug Design Wednesday 15:35-17:00 |
| II-20 Thomas Bouillon Comparison and selection of dosing regimens by discretization, optimizing efficacy and evaluating exposure demonstrated for KAE609 (Cipargamin) Wednesday 15:35-17:00 |
| II-24 Simona Catozzi Inter-species and in vitro-in vivo scaling for quantitative modeling of whole-body drug pharmacokinetics in patients: Application to the anticancer drug oxaliplatin Wednesday 15:35-17:00 |
| II-32 Jared Cui Incorporating complex drug PK with multiple binding targets into a QSP model to predict combined PD effects Wednesday 15:35-17:00 |
| II-55 Janice Goh A translational toolkit to predict clinical Phase IIb/III outcomes from preclinical mouse studies Wednesday 15:35-17:00 |
| II-59 Sofia Guzzetti An integrated modelling approach for targeted degradation: insights on optimisation, data requirements and PKPD predictions from semi- or fully-mechanistic models and exact steady state solutions Wednesday 15:35-17:00 |
| II-60 Chihiro Hasegawa Exploring simplification of a target-mediated drug disposition (TMDD) model for bispecific antibodies for potential application to data-driven modelling Wednesday 15:35-17:00 |
| II-66 Vijay Ivaturi Novel convolution-based In vitro-In vivo correlation (IVIVC) model with time scaling and bioavailability sub-models for, JORNAY PM®, a methylphenidate hydrochloride delayed-release and extended-release capsule Wednesday 15:35-17:00 |
| II-70 Woojin Jung Fractal kinetic implementation in population modeling Wednesday 15:35-17:00 |
| II-77 Niklas Korsbo DeepPumas for automatic discovery of individualizable functions governing longitudinal patient outcomes Wednesday 15:35-17:00 |
| II-78 Anis Krache Modelling selective cell targeting through avidity to inform bispecific antibody discovery and development Wednesday 15:35-17:00 |
| II-80 Jialin Mao Shared Learning from a Physiologically-Based Pharmacokinetic Modeling Strategy for Human Pharmacokinetics Prediction through Retrospective Analysis of Genentech Compounds Wednesday 15:35-17:00 |
| II-81 Francois Mercier Bridging the gap between two-stage and joint models: The case of tumor growth inhibition and overall survival models Wednesday 15:35-17:00 |
| IV-12 Raphaela Gessele How to inform a QSP model with gene expression data – exemplified with a model on intestinal epithelial integrity and RIPK2 inhibition Thursday 15:25-16:55 |
| IV-39 Sebastian Micluța-Câmpeanu Automatic model discovery in Quantitative Systems Biology Thursday 15:25-16:55 |
| IV-56 Morgane PHILIPP Impact of covariate model selection methods on covariate effects and their uncertainty in population pharmacokinetic analysis Thursday 15:25-16:55 |
| IV-59 Fatiha Rachedi Predicting Motor function scores using uHex4 biomarker effect in Pompe disease Thursday 15:25-16:55 |
| IV-60 Christopher Rackauckas Robust Parameter Estimation of Rational Ordinary Differential Equations for NLME and QSP Thursday 15:25-16:55 |
| IV-61 Christopher Rackauckas Uncertainty quantified discovery of chemical reaction systems via Bayesian scientific machine learning Thursday 15:25-16:55 |
| IV-67 Soroush Safaei Developing a PBPK/PD/Tox Modelling Framework for NANOBODY® Drug Conjugates Thursday 15:25-16:55 |
| IV-74 Sebastiaan Sassen The importance of model selection for a priori model informed precision dosing of vancomycin Thursday 15:25-16:55 |
| IV-78 Marie Steinacker Non-linear autoregressive exogenous modelling to predict individual haematotoxicity during chemotherapy Thursday 15:25-16:55 |
| IV-94 Daichi Yamaguchi Population pharmacokinetic modelling for vancomycin using Bayesian model averaging approach Thursday 15:25-16:55 |
